Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

To Evaluate Real-World Effectiveness of Osimertinib for Patients With Advanced or Metastatic Epidermal Growth Factor Receptor 20exon Insertion Mutation (20ins) Non-Small Cell Lung Cancer (NSCLC)

NCT05513664 is registered in ClinicalTrials.gov with Shanghai JMT-Bio Inc. as lead sponsor.

NCT NCT05513664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05513664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
To Evaluate Real-World Effectiveness of Osimertinib for Patients With Advanced or Metastatic Epidermal Growth Factor Receptor 20exon Insertion Mutation (20ins) Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Shanghai JMT-Bio Inc.
Phase
Observational
Overall status
Unknown status
Start date
September 30, 2022
Completion date
August 31, 2023
Enrollment
80 (estimated)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

egfr exon20 insertion mutations, locally advanced or metastatic non-small cell lung cancer